Ardelyx, Inc.

Ardelyx, Inc. is a biotechnology company that discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and globally. The company currently markets two products: IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation (IBS-C), and XPHOZAH, a phosphate absorption inhibitor used to reduce serum phosphorus in adults with chronic kidney disease (CKD) who are on dialysis. Ardelyx focuses on addressing gastrointestinal and kidney-related conditions, leveraging its expertise in small molecule drug development to provide targeted therapies for patients with limited treatment options.

Ardelyx, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ARDX. The company's shares are traded in U.S. dollars (USD), which is the official currency of the United States. As a Nasdaq-listed company, Ardelyx is subject to the exchange's listing requirements and regulatory oversight, providing investors with a transparent and regulated trading environment. The NasdaqGM is a tier of the Nasdaq Stock Market that includes companies meeting specific financial and liquidity standards.

Ardelyx, Inc. operates within the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, Ardelyx focuses on researching, developing, and commercializing innovative therapies for diseases with significant unmet medical needs. The biotechnology industry is characterized by high research and development costs, long product development cycles, and reliance on regulatory approvals. Ardelyx's specific focus on gastrointestinal and kidney diseases places it within the therapeutic areas of gastroenterology and nephrology, which are key subfields of biotechnology.

Ardelyx, Inc. is headquartered in Waltham, Massachusetts, United States. The company was incorporated in 2007 and was formerly known as Nteryx, Inc. before changing its name to Ardelyx in June 2008. Ardelyx serves patients in the United States and globally, with its commercial products IBSRELA and XPHOZAH available in the U.S. market. The company's global presence includes efforts to expand access to its therapies through partnerships and regulatory submissions in other countries, though specific international markets are not detailed in the available data.

Ardelyx, Inc. has two main commercial products: IBSRELA and XPHOZAH. IBSRELA (tenapanor) is a minimally absorbed small molecule therapy indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. It works by inhibiting the sodium-hydrogen exchanger NHE3, which increases intestinal fluid and accelerates transit time, thereby relieving constipation and abdominal pain. XPHOZAH (tenapanor) is a phosphate absorption inhibitor used to reduce serum phosphorus levels in adults with chronic kidney disease (CKD) on dialysis. It acts locally in the gut to block the paracellular absorption of phosphate, helping to manage hyperphosphatemia. Both products address significant unmet needs in gastrointestinal and kidney health.